AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04777071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT05645029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glass ionomer-chlorhexidine
Description: chlorhexidine will be added to glass ionomer
Study NCT05645029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glass ionomer-titanium dioxide powder
Description: titanium dioxide will be added to glass ionomer
Study NCT05645029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glass ionomer
Description: glass ionomer will be used without any additives
Study NCT05427825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS anesthetic care
Description: The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
Study NCT05427825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard anesthetic care
Description: The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
Study NCT05155696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Kefir probiotic drink (supplied by Nourish)
Description: 125ml per day of dairy based probiotic drink (Kefir) containing ≥ 50billion colony forming units (CFU), supplied in plain packaging.
Study NCT05155696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 125ml of non-fermented dairy based placebo (UHT milk) per day, supplied in plain packaging.
Study NCT04777071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT04777071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT04777071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MR scan
Study NCT04777071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT04527016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiota and eosinophils based therapy
Description: 1. Blood eosinophils ≥3%+ mixed airway microbiota: 3 month course of FP 50 ug twice daily via spacer~2. Blood eosinophils\<3%+ Moraxella species>40% in airway microbiota: Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~3. Blood eosinophils ≥3%+ Moraxella species>40% in airway microbiota: 3 month course of FP 50 ug twice daily via spacer and Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~4. Blood eosinophils\<3%+ mixed airway microbiota: intermittent budesonide inhalation suspension (1mg twice daily) and terbutaline inhalation suspension for 7 days during wheeze episode.~The participants will be followed up for one year after the intervention.
Study NCT04527016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinical guidelines based therapy
Description: The children will be treated as directed by their paediatrician ( The clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016).The treatment protocols include:~1. regular inhaled FP 50 ug twice daily via spacer for 3 months;~2. montelukast(4mg od for 3 months)~3. intermittent budesonide inhalation suspension (1mg twice daily for 7 days during wheeze episode).~The participants will be followed up for one year after the intervention.
Study NCT05359939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18F-FDGal PET/CT versus 18F-choline PET/CT
Description: Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
Study NCT06552585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-weeks weight prevention program
Description: Twice a week, over 12-weeks, the weight program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with two weights Domyos with 1, 2, 3, 4, or 5 kg.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
Study NCT06552585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-weeks elastic band prevention program
Description: Twice a week, over 12-weeks, the elastic band program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with an elastic band Bodytone Power Band with 10, 15, 20, 25, or 30 kg weights Domyos.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
Study NCT06552585 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: The control group performed a sham intervention, twice a week, for 12-weeks. This intervention consisted of 2 sets of 10 repetitions of 5 shoulder mobility exercises, without preventive aim, normally carried out in warm-up before training: shoulder maximum flexion and extension, horizontal abduction and adduction starting from 90º of shoulder abduction, maximum internal/external rotation starting from 90º of shoulder abduction, circumduction of the shoulder in a clockwise direction and circumduction of the shoulder in a counterclockwise direction. There was no progression after 6-weeks of this sham intervention. The coach of the respective team checked the execution of the exercises, but there was no individualized monitoring with a regular exercise technique correction by a physiotherapist.
Study NCT06552520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2722 injection
Description: Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody
Study NCT06552520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of TQH2722 injection
Description: Placebo without drug substance
Study NCT04928157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP)
Description: A device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
Study NCT06091436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci094
Description: On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
Study NCT05126368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: During cataract surgery the Eyhance toric II intraocular lens will be implanted in one eye of the patient
Study NCT06091436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo RecFSH / follitropin alfa
Description: powder-injection, but without the active ingedient, SC injection . Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
Study NCT06091436 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: RecFSH / Follitropin alfa (Days 1 to 7)
Description: Daily SC injections with 150IU or 225IU recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
Study NCT06091436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo GenSci094
Description: Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
Study NCT04510194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.
Study NCT04510194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo; appearance and size are exact matching to the three study drugs.
Study NCT04510194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14
Study NCT04510194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
Study NCT06156384 — intervention group
Intervention type: DEVICE
Intervention: FITBONE® Lengthening Nail
Description: The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter.~After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation.
Study NCT05046314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK216+Vincristin
Description: TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle，every 28 days is a study cycle.
Study NCT04670965 — intervention group
Intervention type: BIOLOGICAL
Intervention: E-PRF/rhBMP-2 (similar ratios)
Description: During its preparation, 1.5 mg/ml rhBMP-2 will be incorporated into standardized samples to assure similar E-PRF to rhBMP-2 ratios. To allow for consistency across all samples, standardized E-PRF volume will be established using formation templates. Following its preparation, the E-PRF/rhBMP2 scaffold will undergo a standard in vitro assay to investigate growth factor release over time (ELISA quantification assay). Briefly, the e-PRF/rhBMP2 scaffold will be placed in a shaking incubator at 37 degree Celsius and assessed for growth factor release of rhBMP-2 over time.
Study NCT04670965 — intervention group
Intervention type: BIOLOGICAL
Intervention: E-PRF/ACS/rhBMP-2
Description: rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. After the addition of the rhBMP-2, the ACS will be cut into 2mm x 2mm pieces and incorporated into the E-PRF membrane. Following its preparation, rhBMP-2 release from the E-PRF/ACS/rhBMP2 scaffold will be quantified using the ELISA quantification assay as described above.
Study NCT04670965 — intervention group
Intervention type: BIOLOGICAL
Intervention: rhBMP-2/E-PRF
Description: rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. Rh-BMP2 release will be quantified using the ELISA quantification assay as described above
Study NCT04670965 — intervention group
Intervention type: BIOLOGICAL
Intervention: E-PRF only
Description: E-PRF will be prepared and standardized, but no rhBMP-2 will be added to the material. After preparation, the E-PRF scaffold assayed via ELISA quantification assay as described above to determine the release (if any) of intrinsic BMP-2 from the platelet concentrate scaffold.
Study NCT06475742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: Film-coated tablets at a dose of 4 mg.
Study NCT06091436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RecFSH / Follitropin alfa (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.
Study NCT06091436 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RecFSH / Follitropin alfa (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.
Study NCT06091436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
Study NCT06091436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
Study NCT06091436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCG
Description: When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
Study NCT06091436 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
Study NCT06091436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
Study NCT06091436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
Study NCT05993403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intercultural Sensitivity Education Program
Description: The training program consists of three sessions. In the Intercultural Sensitivity training for nurses, it was aimed to develop the level of intercultural sensitivity, and it was aimed to provide proficiency in providing services to raise awareness and knowledge about intercultural sensitivity.
Study NCT05201768 — intervention group
Intervention type: OTHER
Intervention: balance tests,questionnaire
Description: Individuals will be tested and recorded.
Study NCT06607965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein and Carbohydrates
Description: Experimental Group:~6 hours before surgery, patients orally consumed 250 ml of a full-nutrition liquid (220 ml homogenized diet, 50 g; containing 31.4 g carbohydrates, 8 g protein, and 215 kcal).~2 hours before surgery, patients orally consumed 200 ml of a clear liquid (50 g enzymatically hydrolyzed rice powder + 0.5 g low-sodium salt; containing 47.7 g carbohydrates, 6.5 g whey protein, and 193 kcal).~After surgery, once there were no symptoms such as dizziness or vomiting, patients could start consuming clear liquids (containing 47.7 g carbohydrates, 6.5 g protein, and 221 kcal) orally every 30 minutes, 4 times on the day of surgery.~Starting from the first day after surgery, patients consumed 200 ml of fat-free nutritional liquid (50 g enzymatically hydrolyzed rice powder + 7.5 g isolated whey protein + 0.5 g low-sodium salt; 223 kcal) per serving, 4 to 6 times per day as needed.
Study NCT06599021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscular strengthening training
Description: 6 weeks daily muscular strengthening training.
Study NCT06599021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skill-based training
Description: 15 sessions skill based swallowing training lead by a speech and language pathologist during 3 weeks.
Study NCT06600685 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functionally oriented music therapy (FMT)
Description: There are different methods of music therapy and one of these is FMT. It is a body-based and music therapeutic treatment method that is used for health-promoting purposes. With the help of i.e. drums, cymbals, various custom-made drumsticks, flutes, chairs, balance balls and balance cushions. FMT strives to support, strengthen and develop the person's physical, mental and social abilities. FMT-sessions (20 minuets/1 time a week) are performed individuelly (a patient with a educated music therapist).
Study NCT06601387 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: choledochoduodonostomy
Description: surgical drainage procedures
Study NCT05057793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: geko
Description: The geko device will be self-administered and deliver 12 hours of therapy daily.
Study NCT05774652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention Dietary advise and/or advise on physical activity
Description: Lifestyle intervention Dietary advise and/or advise on physical activity
Study NCT06601387 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: hepaticojejunostomy
Description: surgical intervention
Study NCT04886739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGB-400
Description: Topical gel
Study NCT04886739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Topical gel
Study NCT06611176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local levobupivacaine
Description: submucosal injection of levobupivacaine during esophageal esad
Study NCT06609863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dTACE-HAIC
Description: dTACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then drug-eluting microspheres were used (100-300um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
Study NCT04741607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement (BLX implant system, Straumann, Basel, Switzerland)
Description: Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
Study NCT04741607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement (BLX implant system, Straumann, Basel, Switzerland)
Description: Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
Study NCT04741607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)
Description: Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
Study NCT04741607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)
Description: Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
Study NCT05286541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateralized buccal cortex with xenograft
Description: the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance
Study NCT05286541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateralized buccal cortex with autogenous particulate
Description: lateralized buccal cortex with autogenous particulate
Study NCT05328700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Perform a neuromuscular bandage with kinesiotape in patients with plantar fasciitis
Study NCT05328700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tape
Description: Perform a neuromuscular bandage with tape (Hipofix(R)) in patients with plantar fasciitis